Germany’s ambitious move toward the partial legalization of cannabis is facing a sharp rebuke from the nation’s leading medical authorities, who warn that government evaluations are prematurely painting a “too positive” picture of the policy’s impact. While official interim reports suggest that the transition has had little measurable effect on overall population consumption, a coalition of psychiatric and addiction specialists argues that the true public health costs will not be visible for years.
The friction centers on the Germany cannabis partial legalization medical concerns surrounding the Konsumcannabisgesetz (CanG), often referred to in evaluation circles as EKOCAN. Three of the country’s most influential medical bodies—the German Society for Psychiatry and Psychotherapy, Psychosomatics and Neurology (DGPPN), the German Society for Addiction Research and Therapy (DG-Sucht), and the German Society for Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (DGKJP)—have issued a coordinated warning that the government’s second interim report ignores fundamental timelines of addiction science.
At the heart of the dispute is a clash between political reporting and longitudinal research. The government’s current data suggests stability in cannabis use across the general population since the law took effect on April 1, 2024. However, medical experts argue that treating a few months of data as a success is scientifically unsound.
The Lag in Public Health Data
Medical societies argue that the window of observation used in the interim report is far too narrow to capture the systemic shifts associated with legalization. According to Euphrosyne Gouzoulis-Mayfrank, President of the DGPPN, international research indicates that the actual effects of legalization typically only develop into apparent after five years, and more realistically, after a decade.
This time lag creates a dangerous “blind spot” in policy evaluation. Experts from DG-Sucht, including Co-Presidents Eva Hoch and Thomas Hillemacher, emphasize that severe health consequences—such as the development of cannabis use disorder or the onset of cannabis-induced psychosis—do not manifest immediately upon a change in legal status. By claiming a lack of “measurable impact” so early, the societies warn that the government may be ignoring the unhurried-burn escalation of health risks.
Shifting Patterns of Dependency
While the total number of users may remain stable, the nature of that use appears to be shifting toward more dangerous patterns. Michael Kölch, President of the DGKJP, noted a concerning trend: while overall consumption numbers are flat, the proportion of users exhibiting “harmful or dependent consumption patterns” has increased.
This suggests that the law may not be increasing the number of people trying cannabis, but it may be facilitating a deeper, more problematic level of use among existing consumers. This distinction is critical for healthcare providers who must manage the long-term psychiatric fallout of increased dependency.
The ‘Care Gap’ for High-Risk Youth
Perhaps the most urgent concern raised by the medical community is the emergence of a “care gap” (Versorgungslücke) for adolescents. Under the previous prohibitionist regime, the legal system often served as an unintentional gateway to treatment. When youth were caught with cannabis, police and justice departments frequently utilized “diversion” programs, requiring the minor to attend addiction counseling or early intervention services in exchange for avoiding a criminal record.
With the partial legalization, this primary mechanism for identifying at-risk youth has vanished. The DGKJP warns that since the police-to-therapy pipeline has been severed without the creation of equivalent, low-barrier alternative pathways, fewer young people are entering addiction services.
This creates a paradox where the most vulnerable group—adolescents whose developing brains are most susceptible to the effects of THC—are now less likely to be steered toward professional help until a crisis occurs, rather than receiving early intervention.
The Erosion of Medical Boundaries
The medical societies too expressed deep apprehension regarding the evolution of the medicinal cannabis market. Since the regulatory changes, there has been a surge in “low-threshold” access to medical cannabis, often facilitated by digital platforms that bypass the traditional, mandatory personal relationship between a doctor and a patient.
The experts warn that this trend is blurring the line between a legitimate medical indication and recreational use. This “medicalization” of leisure consumption not only risks the misuse of the drug but also undermines the clinical integrity of cannabis as a therapeutic tool for patients with severe chronic conditions.
| Metric | Interim Report View | Medical Society View |
|---|---|---|
| Consumption Levels | Little to no measurable increase | Too early to inform; effects take 5–10 years |
| Youth Access | Focus on regulatory barriers | Critical “care gap” due to lost legal referrals |
| Usage Quality | Stable population numbers | Increase in harmful/dependent patterns |
| Medical Market | Expanded patient access | Blurring of medical vs. Recreational lines |
Disclaimer: This article is for informational purposes only and does not constitute medical or legal advice. Individuals seeking treatment for substance use should consult a licensed healthcare professional.
The next critical checkpoint for the Konsumcannabisgesetz will be the subsequent phase of the government’s evaluation process, which is expected to integrate more comprehensive health data as the observation period extends. Until then, the medical community remains in a state of high alert, urging policymakers to prioritize psychiatric infrastructure over optimistic short-term data.
What do you think about the balance between legalization and public health safeguards? Share your thoughts in the comments or share this story on social media.
